A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension
about
A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER studyLatanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
P2860
A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@ast
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@en
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@nl
type
label
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@ast
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@en
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@nl
prefLabel
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@ast
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@en
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@nl
P2093
P2860
P356
P1433
P1476
A 4-week, dose-ranging study c ...... aucoma and ocular hypertension
@en
P2093
Carla Starita
Charles Tressler
David Eveleth
P2860
P2888
P356
10.1186/1471-2415-12-9
P577
2012-05-18T00:00:00Z
P5875
P6179
1002064217